Top Story Today
Lilly Bets $7.8 Billion on a Biotech You've Probably Never Googled
Eli Lilly is acquiring Centessa Pharmaceuticals for up to $7.8 billion, paying $38 per share in cash (a 40.5% premium) plus contingent payouts tied to FDA approvals. The prize: cleminorexton, an OX2R agonist that aims to treat narcolepsy and sleep disorders by replacing a missing brain chemical rather than masking symptoms. The drug is still in Phase 2, which makes this Lilly's most aggressive early-stage bet yet. It's the company's third acquisition of 2026, and it comes as neuroscience M&A surpassed oncology deal volume for the first time last year.
Why it matters: CNS deals overtook oncology as the hottest M&A category in pharma in 2025. Lilly paying a nearly $8 billion premium for a Phase 2 asset signals that the competition for brain-focused biotechs is reaching a fever pitch, and late movers will pay even more.
Read more →Deals and Dollars
Biogen Drops $5.6 Billion (and a 140% Premium) on Apellis
A 140% premium tells you how badly Biogen wanted this. The company is paying $5.6 billion in cash for Apellis Pharmaceuticals, which sells two approved drugs targeting the complement system (your immune system's overzealous first responder). Apellis generated approximately $1 billion in 2025 revenue, and the deal caps a three-year strategy to build a complement disease powerhouse.
Read more →Novo Nordisk Paid $700M for a Drug. Now It Wants Every Penny Back.
Novo Nordisk is accusing KBP Biosciences of hiding negative clinical data before a $1.3 billion licensing deal for a blood pressure drug that later failed in Phase 3. KBP counters that Novo had a full data room and never opened key files. A worldwide asset freeze is already in place, with $830 million in damages at stake.
Read more →U.S. VCs Are Writing Checks in Chinese Labs Before Data Gets Published
Chinese biotech out-licensing hit $135.7 billion in 2025, nearly ten times the 2021 level. U.S. venture firms like RA Capital are now embedding in Chinese labs, investing before research is even published to beat local competitors. The strategy has produced billion-dollar exits, but geopolitical risks (including the BIOSECURE Act) loom large.
Read more →Clinical Milestones
A Brand-New Class of Genetic Medicine Just Entered the Clinic
Alltrna's AP003 just became the first-ever tRNA therapy tested in humans, launching a Phase 1 trial in Australia. The concept: an engineered molecule that overrides a specific DNA typo (nonsense mutations) regardless of which disease it causes. About 10% of genetic diseases stem from these mutations, making this a potentially disease-agnostic platform. Think early mRNA vibes, circa 2008.
Read more →A Nine-Patient Eczema Trial Just Put Sanofi on Notice
Enveda Biosciences posted Phase 1b data showing its oral pill ENV-294 delivered an 85% reduction in eczema severity across nine patients by Day 42. For context, Dupixent (Sanofi's $18 billion injectable blockbuster) hit EASI-75 in 44-51% of patients at week 16; ENV-294 reached 78% in six weeks. Tiny trial, huge implications if it replicates.
Read more →A Small Biotech Just Picked a Phase 3 Fight With Pfizer in Prostate Cancer
Oric Pharmaceuticals is planning a global Phase 3 trial for rinzimetostat in advanced prostate cancer. The drug works by reversing tumor resistance to existing therapies, and preclinical data showed it outperformed Pfizer's competing molecule. In Phase 1b, 55% of patients saw their PSA levels drop by half.
Read more →Industry Shakeups
From 'Most Innovative Biotech' to Chapter 7 in Twelve Months
IO Biotech filed for total liquidation after its cancer vaccine missed statistical significance with a p-value of 0.0558. The drug showed 19.4 months progression-free survival versus 11 months for the standard of care, but the FDA said don't bother filing. Every employee was terminated; shareholders will likely get nothing.
Read more →Takeda Cuts 634 U.S. Jobs to Fund Its Next Wave of Drug Launches
Takeda is eliminating 634 U.S. positions (nearly 40% in Cambridge, MA) to generate over $1.25 billion in annual savings. The cuts will fund three pivotal drug launches.
Read more →NIH Director Quoted the Father of U.S. Science Funding. Scientists Say He Got It Backward.
NIH Director Jay Bhattacharya invoked Vannevar Bush's 1945 vision for American science at CPAC to defend the administration's research overhaul. Researchers fired back: Bush's core argument was that government should fund science generously and let scientists allocate the money. Over $12 billion in grants have been terminated on Bhattacharya's watch.
Read more →